Home >> Pharmaceuticals >> Food & Beverage >>

Hepatitis C Drug Market for (Hospitals, Private Labs, Physician Offices, Public Health Labs and Blood Banks) by Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021

Published: Jun-2016 | Format: PDF | Zion | Number of pages: 110 | Code: MRS - 62423

The report covers forecast and analysis for the market on a global and regional level. The study provides historic data of hepatitis C drug market 2015 along with a forecast from 2016 to 2021 based on revenue (USD billion). The study includes drivers and restraints for the hepatitis C drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hepatitis C drug market on a global level.

In order to give the users of this report a comprehensive view on the hepatitis C market, we have included a detailed competitive scenario and type portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the hepatitis C drug market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.

The study provides a decisive view on the hepatitis C drug market by segmenting the market based on applications. All the application segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Hospitals, private labs, physician offices, public health labs, and blood banks are the key application of the hepatitis C drug market. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further bifurcation into major countries including U.S., Canada, Germany, France, UK, China, Japan, India and Brazil. This segmentation includes demand for hepatitis C drug based on individual applications in all the regions and countries.

Some of the key player in the hepatitis C drug market includes Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.

The report segments the global hepatitis C drug market as

Hepatitis C Drug Market: Application Segment Analysis

  • Hospitals
  • Private labs
  • Physician offices
  • Public health labs
  • Blood banks

Hepatitis C Drug Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • Germany
    • UK
    • France
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa
  • Chapter 1. Preface
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global hepatitis C drug market, 2015 - 2021, (USD Billion)
    • 2.2. Hepatitis C drug: market snapshot
  • Chapter 3. Hepatitis C Drug Market: Industry Analysis
    • 3.1. Hepatitis C drug : Market dynamics
    • 3.2. Market Drivers
      • 3.2.1. Increasing incidences of the disease
      • 3.2.2. New efficient therapies and comparatively smaller period of treatment
      • 3.2.3. Rising government funding
    • 3.3. Restraints
      • 3.3.1. Lack of awareness and information about HCV
      • 3.3.2. Treatment cost
      • 3.3.3. Threat related with regulation and development of drug
    • 3.4. Opportunity
      • 3.4.1. Advancing technologies and ongoing research
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by application segment
      • 3.6.2. Market attractiveness analysis by regional segment
  • Chapter 4. Global hepatitis C drug market: Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global hepatitis C drug market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Product and Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Product Portfolio
    • 4.5. Patent Analysis (2011-2016)
      • 4.5.1. Patent Trend
      • 4.5.2. Patent Share by company
      • 4.5.3. By Region
  • Chapter 5. Global hepatitis C market: Application Overview
    • 5.1. Global hepatitis C drug market share, by application, 2015 and 2021
    • 5.2. Global hepatitis C drug market for hospitals, 2015 - 2021(USD Billion)
    • 5.3. Global hepatitis C drug market for private labs , 2015 - 2021 (USD Billion)
    • 5.4. Global hepatitis C drug market for physician offices, 2015 - 2021 (USD Billion)
    • 5.5. Global hepatitis C drug market for public health labs, 2015 - 2021 (USD Billion)
    • 5.6. Global hepatitis C drug market for blood banks, 2015 - 2021 (USD Billion)
  • Chapter 6. Global hepatitis C drug market: Regional Analysis
    • 6.1. Global hepatitis C drug market: Regional overview
      • 6.1.1. Global hepatitis C drug market share, by region, 2015 and 2021
    • 6.2. North America
      • 6.2.1. North America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.2.2. U.S.
      • 6.2.3. U.S. hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
    • 6.3. Europe
      • 6.3.1. Europe hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.3.2. UK
        • 6.3.2.1. UK hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.3.3. France
        • 6.3.3.1. France hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.3.4. Germany
        • 6.3.4.1. Germany hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
    • 6.4. Asia Pacific
      • 6.4.1. Asia-Pacific hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.4.2. China
        • 6.4.2.1. China hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.4.3. Japan
        • 6.4.3.1. Japan hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.4.4. India
        • 6.4.4.1. India hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
    • 6.5. Latin America
      • 6.5.1. Latin America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.5.2. Brazil
        • 6.5.2.1. Brazil hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
    • 6.6. Middle East & Africa
      • 6.6.1. Middle East & Africa hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. Merck & Co
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product portfolio
      • 7.1.4. Business strategy
      • 7.1.5. Recent developments
    • 7.2. Kenilworth
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product portfolio
      • 7.2.4. Business strategy
      • 7.2.5. Recent developments
    • 7.3. Roche
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product portfolio
      • 7.3.4. Business strategy
      • 7.3.5. Recent developments
    • 7.4. Basel Glaxosmith
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product portfolio
      • 7.4.4. Business strategy
      • 7.4.5. Recent developments
    • 7.5. Gilead Sciences
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product portfolio
      • 7.5.4. Business strategy
      • 7.5.5. Recent developments
    • 7.6. Abbvie
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product portfolio
      • 7.6.4. Business strategy
      • 7.6.5. Recent developments
    • 7.7. Bristol- Myers Squibb.d
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product portfolio
      • 7.7.4. Business strategy
      • 7.7.5. Recent developments
    • 7.8. Johnson & Johnson
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product portfolio
      • 7.8.4. Business strategy
      • 7.8.5. Recent Developments
  • Chapter 8. Patents
    • 8.1. U.S. (US Patents)
    • 8.2. Europe (EP documents)
    • 8.3. Japan (Abstracts of Japan)
    • 8.4. Global (WIPO (PCT))

List of Tables

1. Global hepatitis C drug market snapshot
2. Drivers for hepatitis C drug market: Impact analysis
3. Restraints of hepatitis C drug market: Impact analysis
4. North America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
5. U.S. hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6. Europe hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
7. UK hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
8. France hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
9. Germany hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
10. Asia-Pacific hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
11. China hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
12. Japan hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
13. India hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
14. Latin America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
15. Brazil hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
16. Middle East & Africa hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)


List of Figures

1. Global hepatitis C drug market segmentation by application, and geography
2. Global hepatitis C drug market, 2015 - 2021 (USD Billion)
3. Porter’s five forces analysis: Hepatitis C drug market
4. Market attractiveness analysis by application segment
5. Market attractiveness analysis by regional segment
6. Global hepatitis C drug market : Company Market Share, 2015
7. Price Trend Analysis : Hepatitis C drug market  
8. Patent trend between 2011 -2016
9. Patent Share by Company between 2011 - 2016
10. Patent Share by Region between 2011 - 2016
11. Global hepatitis C drug market share, by application, 2015 -2021
12. Global hepatitis C drug market for hospitals, 2015 - 2021 (USD Billion)
13. Global hepatitis C drug market for private labs, 2015 - 2021 (USD Billion)
14. Global hepatitis C drug market for physician offices, 2015 - 2021 (USD Billion)
15. Global hepatitis C drug market for public health labs, 2015 - 2021(USD Billion)
16. Global hepatitis C drug market for blood banks, 2015 - 2021 (USD Billion)
17. Global hepatitis C drug market share, by region, 2015 - 2021
18. North America hepatitis C drug market, 2015 - 2021, (USD Billion)
19. U.S. hepatitis C drug market, 2015 - 2021, (USD Billion)
20. Europe hepatitis C drug market, 2015 - 2021, (USD Billion)
21. UK hepatitis C drug market, 2015 – 2021, (USD Billion)
22. France hepatitis C drug market, 2015 - 2021, (USD Billion)
23. Germany hepatitis C drug market, 2015 - 2021, (USD Billion)
24. Asia Pacific hepatitis C drug market, 2015 – 2021, (USD Billion)
25. China hepatitis C drug market, 2015 - 2021, (USD Billion)
26. Japan hepatitis C drug market, 2015 – 2021, (USD Billion)
27. India hepatitis C drug market, 2015 - 2021, (USD Billion)
28. Latin America hepatitis C drug market, 2015-2021, (USD Billion)
29. Brazil hepatitis C drug market, 2015 - 2021, (USD Billion)
30. Middle East & Africa hepatitis C drug market, 2015 - 2021, (USD Billion)

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Zion Research uses the synergy of combination of both primary research and secondary research for its research reports. For this study, we have conducted extensive primary research, wherein we have conducted in-depth interviews of the key opinion leader of this industry. Primary research make up for the biggest chunk of our data sources in addition to secondary research.

We referred to product literature of leading industry participants, annual reports, press releases, government publications, and other relevant sources for data collection and analysis thereof. Secondary research also includes a search of recent trade journals, technical writing, internet sources, and statistical data from government websites, trade associations and agencies.

Zion Research has collected key data related to the embedded system Market and analyzed these data using a variety of methods. The market dynamics have been ascertained following a detailed study of the micro, meso, and macroeconomic indicators of the market.

This report is based on in-depth qualitative and quantitative analyses of the Global embedded system Market. The quantitative analysis involved the application of various projection and sampling techniques. The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions.

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically partake in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Based on the research results and technical insights thus gathered, Zion research analysts have provided a comprehensive analysis of the varied aspects of the market. The impact of global economic conditions and other macroeconomic indicators was also considered when assessing the market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Hepatitis c is an infection caused by a hepatitis C virus (HCV) that attacks the liver and leads to inflammation. This infection can bring both acute and chronic hepatitis disease. According to world health organization (WHO) 130 to 150 million people globally have chronic hepatitis C infection yearly. No vaccine yet exists for prevention of hepatitis C. Hepatitis C is the most hazardous among all types of hepatitis as 80% of patients get chronically infected. This leads to increased worldwide efforts for the development of hepatitis C drugs. Hepatitis C infection (HCV) spreads through the blood of contaminated individual by the utilization of shared needles or supplies used to infuse drugs.

Increasing incidences of this disease is major driving factors for hepatitis C drug market. New efficient therapies are expected to drive the hepatitis C drug market in the near future. Furthermore, comparatively smaller period of treatment and rising government funding are the factors that drive the growth of the HCV market. Treatment of the warehoused patients those seek for a better-quality treatment, discounts and better regimens are also expected to fuel the market growth. However, lack of awareness and information about HCV, treatment cost, and threat related with regulation and development of drug may hamper hepatitis C drug market.

Global Hepatitis C-Market

Hepatitis C drug market is segmented based on different application sectors of hepatitis C infection drugs. Hospitals, private labs, physician offices, public health labs, and blood banks are the key application areas of the hepatitis C drug market. Hospital and labs are the major segments and expected to be the fastest growing applications in forthcoming years.

North America was the largest regional market for hepatitis C Market in 2015. It accounted for over 40% share of the total revenue generated in the same year. In this region U.S. is the largest revenue contributor for global Hepatitis C drug market. Further it is expected to continue this trend during near future owing to ongoing research and development in pharmaceutical industry. Europe was the second largest market for Hepatitis C drugs. Further, demand for Hepatitis C drug is increasing in Asia Pacific, Latin America and Middle East & Africa region due to prevalence of the diseases in these regions coupled with increasing expenditure on healthcare infrastructure over the years to come.

There was no appropriate treatment present for HCV before 2010, however new treatments like Sovaldi and Harvoni by Gilead and Viekira Pak by AbbVie have transformed the market situation. Some of the key player in the global hepatitis C market includes Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb

  • Payment Mode
Single User | $(USD)4199 View Pricing